NCT00478023

A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy

A Randomized, Double-blind, Parallel-arm, Placebo- and Comparator- Controlled Trial of the Efficacy and Safety of Multiple Doses of Immediate-release (IR) CG5503 for Postoperative Pain Following Abdominal Hysterectomy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 854 (actual)
• Sponsor: Grünenthal GmbH · Industry
• Sex: Female
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to demonstrate the efficacy and safety of multiple-dose application of three different oral doses of CG5503 IR (tapentadol immediate release) compared to placebo in women undergoing abdominal hysterectomy.

Detailed description

Subjects undergoing abdominal hysterectomy often experience moderate to severe acute pain post-surgery. Normally such pain is controlled when subjects receive repeated doses of opioid analgesics. However, opioid therapy is commonly associated with side effects such as nausea, vomiting, sedation, constipation, addiction, tolerance, and respiratory depression. Tapentadol (CG5503), a newly synthesized drug with an immediate release (IR) formulation, also acts as a centrally acting pain reliever but has a dual mode of action. The aim of this study is to investigate the effectiveness (level of pain control) and safety (side effects) of 3 dose levels of CG5503 IR compared with no drug (placebo) or one dose level of morphine (an opioid commonly used to treat post-surgical pain). This study is a randomized, double-blind (neither investigator nor patient will know which treatment was received), active- and placebo-controlled, parallel-group, multicenter study to evaluate the treatment of acute pain after abdominal hysterectomy. The study will include a blinded 72 hour in-patient phase immediately following hysterectomy, during which subjects will be treated with either 50-, 75-, or 100-mg CG5503 IR, a matched placebo, or 20-mg morphine, and pain relief will be periodically assessed. Assessments of pain relief include the pain intensity numeric rating scale (PI), pain relief numeric rating scale (PAR), and patient global impression of change scale (PGIC). Safety evaluations include monitoring of adverse events, physical examinations, and clinical laboratory tests. Venous blood samples will be collected for the determination of serum concentrations of CG5503 and morphine. The alternative study hypothesis is that at least 1 dose strength of CG5503 will be different from placebo in controlling pain at 24 hours (using the mean SPID at 24 hours).

Conditions

• Hysterectomy
• Postoperative

Interventions

Type	Name	Description
DRUG	Morphine	20 mg IR; 4 - 6 hourly; Total 72 hours
DRUG	CG5503 IR	50mg; 4 - 6 hourly; Total 72 hours
DRUG	CG5503 IR	75mg; 4 -6 hourly; Total 72 hours
DRUG	CG5503 IR	100mg, 4 - 6 hourly; Total 72 hours
DRUG	Placebo	4 - 6 hourly; Total 72 hours

Timeline

• Start date: 2007-05-01
• Primary completion: 2008-02-01
• Completion: 2008-04-01
• First posted: 2007-05-24
• Last updated: 2019-10-28
• Results posted: 2010-01-27

Locations

52 sites across 9 countries: Hungary, Latvia, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Ukraine